About Us

DEVELOPING HIGH POTENCY AND LOW TOXICITY TARGETED THERAPEUTICS

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.

Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies.

NEWS

EVENTS

EVENTS

No events at the moment.

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.

Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies.

About Us

OUR VISION & CULTURE

Xcovery is committed to bettering lives by providing superior therapies for cancer patients. Founded in 2006 with a passion of bringing humanity back to cancer treatment, Xcovery set out to improve existing effective treatments.

We not only want to bring that compassion and human touch to our patients, but to our team, our partners and treating physicians.

ALK inhibitor ensartinib

OUR LEADERSHIP

 

Fenlai Tan

Lieming Ding, M.D, Chairman of the Board

Lieming Ding, M.D., serves as Chairman of the Board at Xcovery. Dr. Ding currently is also the chairman and CEO of Betta Pharmaceuticals Co., Ltd. He returned to China from US in 2002 to start Betta Pharmaceuticals Co., Ltd, a company focusing on research and development of innovative drugs. In August 2011, Betta Pharmaceutical launched icotinib (Conmana), the first targeted therapy developed in China for non-small cell lung cancer, which is a milestone for the Chinese anticancer industry. In 2012 and 2014, the WIPO and SIPO of China issued Gold award to icotinib for its two invention patents. Icotinib won the first prize of the National Science and Technology Progress Award in 2016, which is the first time that the chemical and pharmaceutical industry won the prize. In the same year, icotinib also won the China Industry Award, the top accolade of industry sector. To date, icotinib has a total sales revenue of over 3.4 billion RMB and has benefited more than 100,000 patients. Dr. Ding’s accomplishment in Chinese pharmaceutical industry has won him numerous honors, such as distinguished expert of All-China Federation of Returned Overseas Chinese, Deputy of the 12th National Peoples’ Congress, key member of Chinese National Key Special Program of Innovative Drugs, and Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Dr. Ding completed his resident training in pathology at University of Arkansas for Medical Sciences.

LOW TOXICITY therapeutics

Chris Liang, Ph.D., EVP and Chief Scientific Officer

Chris Liang, Ph.D., is the co-founder of Xcovery. He is a leading scientist in the design of protein kinase inhibitors who has authored more than 40 scientific publications and secured more than 50 patents. Dr. Liang is co-developer of Sutent®, an FDA approved multi-kinase inhibitor for resistant gastrointestinal stromal tumors, advanced renal cell carcinoma, and advanced, progressive, well-differentiated pancreatic neuroendocrine tumors, which he developed while serving as director of medicinal chemistry at SUGEN. SUGEN and Sutent® were acquired by Pfizer. Additionally, Dr. Liang served as director of medicinal chemistry at Scripps Research Institute in Florida before starting Xcovery.

Dr. Liang’s research focuses on the design of protein kinase inhibitors by combining computational modeling, medicinal chemistry and broad knowledge in other areas of drug discovery. His recent work has focused on the reduction of toxicity in existing multi-kinase inhibitors. Dr. Liang holds a Ph.D. in theoretical chemistry from Princeton University.

XCovery team

Fenlai Tan, M.D., Ph.D., Chief Medical Officer

Fenlai Tan, M.D., Ph.D., is the Chief Medical Officer of Xcovery. He is responsible for the clinical development of Xcovery’s improved kinase inhibitors. Dr. Tan has been involved in drug development for decades and is especially experienced in clinical study design and implementation for small molecule targeted anti-cancer drugs. Dr. Tan joined Betta Pharmaceuticals Co., Ltd as VP and CMO in 2007 where he successfully led the phase I, II, III and IV clinical trials of icotinib (an EGFR tyrosine kinase inhibitor) for the treatment of advanced NSCLC harboring EGFR mutation. In 2011, icotinib (Conmana), as the first home-grown anti-cancer targeted drug, was approved by CFDA and launched in China. A comment titled “Icotinib: kick-starting the Chinese anti-cancer drug industry” was published together with the clinical data of the icotinib phase III study (ICOGEN) on the prestigious medical journal, Lancet Oncology.
In addition, Dr. Tan oversees the clinical development (phase I-III clinical studies) of many other innovative drugs at Betta in the field of oncology, diabetes, dermatology, ophthalmology, etc. He and his team have conducted more than 30 clinical studies during the past ten years.

Dr. Tan obtained his M.D. from XiangYa School of Medicine and also holds a Ph.D. in medical physiology from University of Arkansas for Medical Sciences. He completed his post-doctoral fellowship at Cleveland Clinic and Medical School of University of Michigan. He is a clinician and a leading biomedical scientist who has authored more than 40 scientific publications and secured more than 20 patents.

OUR LEADERSHIP

 

  • Firstname Lastname, title here

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras dapibus vulputate diam eu pretium. Mauris elit orci, ultricies id fermentum vel, porta et eros. Vestibulum condimentum lectus in convallis feugiat. Sed vulputate fringilla felis. Aliquam ut arcu et dui feugiat scelerisque eu quis diam. Mauris placerat congue dui sit amet blandit. Phasellus condimentum libero vel velit auctor, sit amet tincidunt velit varius. Mauris lacinia porta faucibus. Fusce eu est ac eros vulputate mollis in ac felis. Aenean commodo scelerisque mi sed imperdiet. Donec at hendrerit nisi, eget vestibulum nisi. Sed sit amet magna luctus.

  • Firstname Lastname, title here

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras dapibus vulputate diam eu pretium. Mauris elit orci, ultricies id fermentum vel, porta et eros. Vestibulum condimentum lectus in convallis feugiat. Sed vulputate fringilla felis. Aliquam ut arcu et dui feugiat scelerisque eu quis diam. Mauris placerat congue dui sit amet blandit. Phasellus condimentum libero vel velit auctor, sit amet tincidunt velit varius. Mauris lacinia porta faucibus. Fusce eu est ac eros vulputate mollis in ac felis. Aenean commodo scelerisque mi sed imperdiet. Donec at hendrerit nisi, eget vestibulum nisi. Sed sit amet magna luctus.

  • Firstname Lastname, title here

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras dapibus vulputate diam eu pretium. Mauris elit orci, ultricies id fermentum vel, porta et eros. Vestibulum condimentum lectus in convallis feugiat. Sed vulputate fringilla felis. Aliquam ut arcu et dui feugiat scelerisque eu quis diam. Mauris placerat congue dui sit amet blandit. Phasellus condimentum libero vel velit auctor, sit amet tincidunt velit varius. Mauris lacinia porta faucibus. Fusce eu est ac eros vulputate mollis in ac felis. Aenean commodo scelerisque mi sed imperdiet. Donec at hendrerit nisi, eget vestibulum nisi. Sed sit amet magna luctus.

Strategic Partners

Partnering Drives Innovation

Xcovery has partnered with Betta Pharmaceuticals for the development of ensartinib in China. Betta is also the majority shareholder of Xcovery. The development of X-379 (MET inhibitor) in China is partnered with Anew Pharma.

Xcovery has partnered with Betta Pharmaceuticals for the development of ensartinib in China. Betta is also the majority shareholder of Xcovery. The development of X-379 (MET inhibitor) in China is partnered with Anew Pharma.

JOIN US

Welcome to Xcovery. Welcome to Opportunity.

At Xcovery, we value talent, one of the cornerstones of our success. Our aim is to discover, recruit and retain a staff of exceptional people to maintain our position as an industry leader. Our focus on our employees, whether working at the office or at a remote location, ensures we are operating as one team; it’s our sense of team spirit that truly defines the Xcovery culture

Our commitment to our employees as well as our employees’ engagement is what enables us to do what we love – to promote and advance science. If you are interested in joining our team, we invite you to apply today. Please email your resume and cover letter to humanresources@xcovery.com. We are proud to be an equal opportunity employer. All applicants must be legally authorized to work in the U.S.

Administrative Assistant

An opportunity exists for an ambitious professional to be part of the clinical team in support of Xcovery. Xcovery is a biopharmaceutical company working to improve the lives of patients by developing a pipeline of oncology therapies to target a wide range of advanced tumors. This position offers the right candidate a significant opportunity for career development and growth.

    Administrative Assistant

Check back soon for new and exciting opportunities.

  • Job title 1

    Mauris lacinia porta faucibus. Fusce eu est ac eros vulputate mollis in ac felis. Aenean commodo scelerisque mi sed imperdiet. Donec at hendrerit nisi, eget vestibulum nisi. Sed sit amet magna luctus, facilisis erat quis, sagittis ligula. Aenean dignissim velit quis leo consequat ultricies. Proin quis pretium justo. Vestibulum at eros nisl. Fusce lobortis erat ante, eu cursus sapien molestie at. Pellentesque placerat ante diam, et euismod lacus dictum vel. Phasellus vitae sollicitudin mi.

        Accountant &Office Administrator Description

  • Job title 2

    Mauris lacinia porta faucibus. Fusce eu est ac eros vulputate mollis in ac felis. Aenean commodo scelerisque mi sed imperdiet. Donec at hendrerit nisi, eget vestibulum nisi. Sed sit amet magna luctus, facilisis erat quis, sagittis ligula. Aenean dignissim velit quis leo consequat ultricies. Proin quis pretium justo. Vestibulum at eros nisl. Fusce lobortis erat ante, eu cursus sapien molestie at. Pellentesque placerat ante diam, et euismod lacus dictum vel. Phasellus vitae sollicitudin mi.

        Accountant &Office Administrator Description

CONTACT US

 

Xcovery

11780 U.S. Hwy One, Suite 202

Palm Beach Gardens, FL 33408

Tel: (561) 835-9356

CORPORATE

Corporate Communications

info@xcovery.com

Tel: (561) 835-9356

MEDIA

Media Communications

info@xcovery.com

Tel: (561) 835-9356

Xcovery

11780 U.S. Hwy One, Suite 202

Palm Beach Gardens, FL 33408

Tel: (561) 835-9356

 CORPORATE

Corporate Communications

info@xcovery.com

Tel: (561) 835-9356

MEDIA

Media Communications

info@xcovery.com

Tel: (561) 835-9356